Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARMP Armata Pharmaceuticals	$2.43 -3.2%	$2.26	$0.90 ▼ $2.96	$90.94M	0.99	9,172 shs	11,430 shs
AURA Aura Biosciences	$6.47 +1.6%	$6.61	$4.34 ▼ $12.38	$395.70M	0.46	158,670 shs	135,442 shs
CRVS Corvus Pharmaceuticals	$5.29 +1.9%	$4.34	$2.54 ▼ $10.00	$386.73M	0.42	486,228 shs	365,140 shs
FULC Fulcrum Therapeutics	$6.52 -0.8%	$7.11	$2.32 ▼ $9.90	$355.38M	2.47	991,163 shs	440,655 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARMP Armata Pharmaceuticals	-1.18%	+0.40%	+5.46%	+34.22%	-31.42%
AURA Aura Biosciences	-0.47%	-11.89%	-5.91%	+7.24%	-16.24%
CRVS Corvus Pharmaceuticals	-0.38%	+3.80%	+16.63%	+49.57%	+23.57%
FULC Fulcrum Therapeutics	-0.61%	-4.09%	-7.46%	+7.35%	-30.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARMP Armata Pharmaceuticals	3.0344 of 5 stars	3.5	5.0	2.6	1.7	0.0
AURA Aura Biosciences	1.8756 of 5 stars	3.6	0.0	2.5	2.5	0.0
CRVS Corvus Pharmaceuticals	2.8992 of 5 stars	3.5	2.0	2.3	3.3	0.6
FULC Fulcrum Therapeutics	1.5916 of 5 stars	3.3	1.0	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARMP Armata Pharmaceuticals	3.00	Buy	$9.00	270.37% Upside
AURA Aura Biosciences	3.11	Buy	$22.00	240.03% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	183.55% Upside
FULC Fulcrum Therapeutics	2.63	Moderate Buy	$7.57	16.13% Upside

Current Analyst Ratings Breakdown

Latest ARMP, CRVS, FULC, and AURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	AURA Aura Biosciences	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
7/30/2025	FULC Fulcrum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $5.00
7/29/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $12.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARMP Armata Pharmaceuticals	$5.17M	17.03	N/A	N/A	($1.92) per share	-1.27
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$2.81 per share	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$1.08 per share	N/A
FULC Fulcrum Therapeutics	$80M	4.41	N/A	N/A	$3.96 per share	1.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARMP Armata Pharmaceuticals	-$18.92M	-$1.64	N/A	N/A	N/A	-374.30%	N/A	-24.00%	N/A
AURA Aura Biosciences	-$86.92M	-$1.96	N/A	N/A	N/A	N/A	-64.44%	-54.24%	N/A
CRVS Corvus Pharmaceuticals	-$62.29M	-$1.01	N/A	N/A	N/A	N/A	-28.61%	-18.05%	N/A
FULC Fulcrum Therapeutics	-$9.73M	-$1.22	N/A	N/A	N/A	N/A	-31.05%	-28.96%	N/A

Latest ARMP, CRVS, FULC, and AURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	AURA Aura Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
8/7/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.10	+$0.03	-$0.10	N/A	N/A
7/29/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARMP Armata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARMP Armata Pharmaceuticals	N/A	0.06	0.06
AURA Aura Biosciences	N/A	12.39	12.39
CRVS Corvus Pharmaceuticals	N/A	8.91	8.91
FULC Fulcrum Therapeutics	N/A	24.42	24.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARMP Armata Pharmaceuticals	3.57%
AURA Aura Biosciences	96.75%
CRVS Corvus Pharmaceuticals	46.64%
FULC Fulcrum Therapeutics	89.83%

Insider Ownership

Company	Insider Ownership
ARMP Armata Pharmaceuticals	84.50%
AURA Aura Biosciences	6.30%
CRVS Corvus Pharmaceuticals	28.50%
FULC Fulcrum Therapeutics	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARMP Armata Pharmaceuticals	70	36.23 million	5.62 million	Not Optionable
AURA Aura Biosciences	50	62.12 million	58.21 million	Not Optionable
CRVS Corvus Pharmaceuticals	30	74.51 million	53.28 million	Optionable
FULC Fulcrum Therapeutics	100	54.09 million	50.31 million	Optionable

ARMP, CRVS, FULC, and AURA Headlines

Recent News About These Companies

Fulcrum Therapeutics, Inc. $FULC Shares Sold by Connor Clark & Lunn Investment Management Ltd.

August 20 at 3:41 AM | marketbeat.com

XTX Topco Ltd Takes Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

August 15, 2025 | marketbeat.com

Three Key Reasons Why Securities Class Actions Are Failing on Material Misrepresentation Grounds in the District of Massachusetts

August 14, 2025 | jdsupra.com

Fulcrum Therapeutics (NASDAQ:FULC) Cut to Sell at Wall Street Zen

August 12, 2025 | americanbankingnews.com

Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Lowered by Wall Street Zen

August 10, 2025 | marketbeat.com

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 8, 2025 | globenewswire.com

AIRNA Appoints Tamara Joseph as Chief Legal Officer and Kristina Storey as Head of Regulatory Affairs

August 6, 2025 | finance.yahoo.com

FULC Fulcrum Therapeutics, Inc. - Seeking Alpha

August 5, 2025 | seekingalpha.com

FY2025 EPS Estimates for FULC Raised by Cantor Fitzgerald

August 2, 2025 | marketbeat.com

HC Wainwright Issues Optimistic Outlook for FULC Earnings

August 2, 2025 | marketbeat.com

Leerink Partnrs Has Negative Forecast for FULC Q3 Earnings

August 2, 2025 | marketbeat.com

Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

July 31, 2025 | marketbeat.com

Fulcrum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

July 30, 2025 | msn.com

Fulcrum Therapeutics (NASDAQ:FULC) Upgraded at HC Wainwright

July 30, 2025 | marketbeat.com

Fulcrum Therapeutics shares slide 17% after sickle cell trial results

July 29, 2025 | msn.com

Fulcrum reports data from sickle cell disease trial, posts Q2 results

July 29, 2025 | msn.com

Fulcrum Therapeutics stock falls after sickle cell disease trial results

July 29, 2025 | investing.com

Fulcrum study results suggest a pill can treat sickle cell disease

July 29, 2025 | statnews.comS

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

July 29, 2025 | globenewswire.com

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

July 29, 2025 | globenewswire.com

Fulcrum Therapeutics stock soars ahead of sickle cell trial data

July 29, 2025 | za.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARMP, CRVS, FULC, and AURA Company Descriptions

Armata Pharmaceuticals NYSEAMERICAN:ARMP

$2.43 -0.08 (-3.19%)

As of 04:10 PM Eastern

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

Aura Biosciences NASDAQ:AURA

$6.47 +0.10 (+1.57%)

Closing price 04:00 PM Eastern

Extended Trading

$6.47 0.00 (0.00%)

As of 05:48 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Corvus Pharmaceuticals NASDAQ:CRVS

$5.29 +0.10 (+1.93%)

Closing price 04:00 PM Eastern

Extended Trading

$5.21 -0.08 (-1.51%)

As of 07:57 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Fulcrum Therapeutics NASDAQ:FULC

$6.52 -0.05 (-0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$6.52 0.00 (-0.08%)

As of 04:20 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time